8-K 1 b42924mce8-k.txt THE MEDICINES COMPANY SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 ------------ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2002 The Medicines Company -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Charter) Delaware 000-31191 04-3324394 ------------------------ ------------------------ -------------------------- (State or Other (Commission (I.R.S. Employer Jurisdiction File Number) Identification No.) of Incorporation) 5 Sylvan Way, Suite 200 Parsippany, New Jersey 07054 --------------------------------------------- -------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (973) 656-1616 -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS. On April 23, 2002, The Medicines Company announced its financial results for the first quarter of 2002 and the naming of a new Chief Financial Officer. In a separate announcement on April 23, 2002, The Medicines Company announced that it had filed a Form S-3 Shelf Registration Statement registering 4,000,000 shares of its common stock. The full text of the press releases issued in connection with the announcements is filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits.
Exhibit No. Description ----------- ----------- 99.1 Press release dated April 23, 2002 entitled "The Medicines Company Reports First Quarter 2002 Financial Results, Names New Chief Financial Officer." 99.2 Press release dated April 23, 2002 entitled "The Medicines Company Files Shelf Registration Statement."
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 25, 2002 THE MEDICINES COMPANY By: /s/ Steven H. Koehler ------------------------------------ Steven H. Koehler Vice President and Chief Financial Officer EXHIBIT INDEX
Exhibit No. Description ----------- ----------- 99.1 Press release dated April 23, 2002 entitled "The Medicines Company Reports First Quarter 2002 Financial Results, Names New Chief Financial Officer." 99.2 Press release dated April 23, 2002 entitled "The Medicines Company Files Shelf Registration Statement."